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1 These authors contributed equally to this work.Aggregated forms of the amyloid-b peptide are hypothesized to act as the prime toxic agents in Alz-
heimer disease (AD). The in vivo amyloid-b peptide pool consists of both C- and N-terminally trun-
cated or mutated peptides, and the composition thereof signiﬁcantly determines AD risk. Other
variations, such as biotinylation, are introduced as molecular tools to aid the understanding of dis-
ease mechanisms. Since these modiﬁcations have the potential to alter key aggregation properties of
the amyloid-b peptide, we present a comparative study of the aggregation of a substantial set of the
most common in vivo identiﬁed and in vitro produced amyloid-b peptides.
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Early aggregated forms of the amyloid-b peptide (Ab), which is
generated from the amyloid precursor protein (APP), have been
considered the basis for development of Alzheimer’s disease
(AD) [1,2]. Despite extensive research, the exact link between
Ab and AD remains elusive. One of the underlying reasons is that
APP processing in vivo does not generate a single, well-deﬁned
species. The main cause for peptide heterogeneity stems from
the identiﬁcation of two main APP processing pathways, termed
‘non-amyloidogenic’ and ‘amyloidogenic’. The non-amyloidogenic
pathway involves APP cleavage by a- and c-secretase and gener-chemical Societies. Published by E
Group (NBP), University of
he Netherlands. Fax: +31
n).ates the p3 peptide, an N-terminally truncated form of Ab, while
the amyloidogenic pathway releases Ab by action of b- and
c-secretase [3]. Besides the dual processing of APP generating
either p3 or Ab, the c-secretase cleavage site is ill-deﬁned result-
ing in variation at the C-terminus of Ab [4,5]. As a result thereof,
released Ab peptides vary in length from 27 to 49 amino acids
[6,7]. Additional variation in the in vivo Ab pool is attained by
mutations within the Ab domain of APP. Known mutations induc-
ing familial AD (FAD) include the Flemish (Ala21 to Gly), Dutch
(Glu22 to Gln), Italian (Glu22 to Lys), Arctic (Glu22 to Gly), Iowa
(Asp23 to Asn), and Tottori (Asp7 to Asn) mutations (reviewed by
[8]). An additional source of peptide variation results from the
introduction of biotinylation as a research tool for interaction
studies [9–12]. All modiﬁcations described above could affect
peptide behavior due to altered aggregation properties. In this
study we systematically compared the aggregation behavior of
p3 and Ab peptides resulting from heterogeneous APP processing
as well as a selection of FAD-associated Ab mutants and biotinyl-
ated variants.lsevier B.V. All rights reserved.
A. Vandersteen et al. / FEBS Letters 586 (2012) 4088–4093 40892. Materials and methods
2.1. Ab peptide synthesis
Ab and p3 peptides were produced by JPT (JPT Peptide Technol-
ogies, Germany). Details on peptide synthesis and analysis of pep-
tide identity and purity are described in SI.
2.2. Solubilization of Ab peptides
Peptides were dissolved according to the standard procedure
developed and validated in our laboratory [13]. In short, Ab pep-
tides were dissolved in 1,1,1,3,3,3-hexaﬂuoro-2-propanol (HFIP).
HFIP was evaporated using nitrogen gas and the peptide ﬁlm was
redissolved using dimethyl sulfoxide (DMSO). The peptide was
separated from DMSO by elution from a HiTrapTM desalting col-
umn (GE Healthcare, cat. # 17-1408-01) into a 50 mM Tris pH
7.5 buffer containing 1 mM disodium ethylene-diaminetetraace-
tate (EDTA). The resulting samples were kept on ice until experi-
ments started with a maximum lag time of 30 min. Peptide
concentration was determined using the Coomassie (Bradford)
Protein Assay kit and diluted to 25 lM in 50 mM Tris pH 7.5 buffer
containing 1 mM EDTA. Incubation of Ab peptides occurred for the
given time periods at 25 C under quiescent conditions. This proce-
dure was slightly adapted for the ATR-FTIR samples and is de-
scribed in SI.
2.3. Thioﬂavin T ﬂuorescence
Ab concentrations were adjusted to 1 lM using 50 mM Tris pH
7.5 buffer containing 1 mM EDTA and a ﬁnal concentration of
12 lM Thioﬂavin T (ThT). The ﬁbrillation kinetics of the various
Ab preparations were monitored in situ in a Greiner 96-well plate
using a FLUOstar OPTIMA ﬂuorescence plate reader (BMG LABTECH
GmbH, Germany) at an excitation wavelength of 440 nm and an
emission wavelength of 480 nm. Fluorescence readings were re-
corded every 5 min for a period of 20 h. Measurements were per-
formed as independent triplicates. Recorded values were
averaged and background measurements (buffer containing
12 lM ThT) were subtracted.
2.4. Transmission electron microscopy
After 2 weeks of incubation, Ab aliquots (5 lL) were adsorbed
to carbon-coated Formvar 400-mesh copper grids (Agar Scientiﬁc,
cat. # S162-4) for 1 min. The grids were blotted, washed, and
stained with 1% (wt/vol) uranyl acetate. Samples were studied
with a JEOL JEM-1400 microscope (JEOL Ltd., Tokyo, Japan) at
80 kV. Images were collected from three independently prepared
Ab solutions.
2.5. Dotblot
After 0.5 h of incubation a volume of 5 lL Ab was spotted
onto a nitrocellulose membrane. The membranes were blocked
in phosphate buffered saline containing 0.2% Tween-20 (1 h,
25 C), and incubated (1 h, 25 C) with primary A11 antibody
(Invitrogen, cat. # AHB0052), diluted 1:4000 in 100 mM Hepes,
pH 7.0 [14]. After incubation (0.5 h, 25 C) with a secondary
anti-rabbit-HRP-tagged antibody (Promega, cat. # W4011), di-
luted 1:5000 in phosphate buffered saline containing 0.05%
Tween-20, the membranes were visualized using the Immobi-
lonTM Western chemiluminescent HRP substrate system. Spots
were manually selected and intensities of the spots were ana-
lyzed as mean grey values using ImageJ software [15]. Images
were background subtracted.2.6. Attenuated total reﬂectance-Fourier-transform infrared
spectroscopy
ATR-FTIR spectrawere recorded on an Equinox 55 IR spectropho-
tometer (Bruker Optics, Ettlingen, Germany). Twomicrograms of Ab
was spread on the diamond surface (2  2 mm2) of the internal
reﬂection element (ERI) and was washed with excess milliQ water
to eliminate salts. Excesswaterwas evaporatedunder nitrogenﬂow.
Each spectrum represents themean of 128 repetitions, recorded at a
resolution of 2 cm1. Details on data processing are described in SI.
2.7. Statistical Analysis
The intensities of A11-positive spots as determined with ImageJ
software were further analyzed using the two-tailed unpaired
t-test for signiﬁcance. Signiﬁcant differences are denoted ⁄P < 0.05.
3. Results
We present a comparison of the aggregation proﬁles of an
extensive set of Ab peptides with N- or C-terminal variation,
FAD-related mutations, and biotinylated forms of Ab. Ab peptides
were prepared by peptide synthesis. Identity and purity were con-
ﬁrmed by MALDI-TOF MS and LC–MS (Fig. S1–S4).
3.1. C-terminal elongation increases aggregation propensity and
induces an amorphous ﬁbrillar state
Aggregation kinetics of various Ab lengths were recorded by ThT
ﬂuorescence and two different aggregation proﬁles could be distin-
guished: slow aggregation accompanied with long nucleation times
and high ﬁnal ﬂuorescence intensity were detected for Ab1–37,
Ab1–38 and Ab1–40, while Ab1–42 and Ab1–43 aggregated rapidly with
almost immediate onset resulting in lowﬁnal ﬂuorescence intensity
(Fig. 1A,B). Fibril morphology has been related to different afﬁnities
for ThT binding affecting the extent of ThT ﬂuorescence intensity
[16,17]. Visualization of ﬁbrils by TEM indeed revealed morpholog-
ically distinct aggregates, showing extended negatively-stained ﬁ-
brils for Ab1–37, Ab1–38 and Ab1–40, and heavily intertwined
networks for Ab1–42 and Ab1–43 (Fig. 1C). Structural analysis by
ATR-FTIR at early timepoints conﬁrmed that these peptides adopted
a b-sheet conformation, as seen by strong absorption at 1630 cm1
(Fig. 1E). Apart from affecting ﬁbril properties, increasing peptide
length also leads to amore pronounced oligomerization as detected
through dotblotting with the oligomer-speciﬁc A11 antibody
(Fig. 1D). Ab1–37, Ab1–38 and Ab1–40 showed less oligomer accumula-
tion after 0.5 h of incubation than Ab1–42 and Ab1–43. Accordingly,
ATR-FTIR spectra observed for pre-ﬁbrillar Ab1–42 and Ab1–43 sug-
gested higher b-sheet content compared to oligomers produced
from shorter Ab peptides which appeared more as a mixture of
b-sheet, random coil and a-helical secondary structure elements
(Table 1). This conﬁrms the earlier report that the conversion of
monomeric Ab peptide into oligomers and mature ﬁbrils coincides
with the accumulation of a b-sheet enriched conformation [18].
The shorter Ab1–37, Ab1–38 and Ab1–40 displayed a higher b-sheet in-
dex [calculated as the ratio of the (1695/1630 cm1) intensities]
than the longer Ab1–42 and Ab1–43. This suggests a higher content
of antiparallel b-strands which reﬂects a less extended conversion
from the oligomeric, antiparallel conformation into theﬁbrillar, par-
allel conformation after 1.5 h of incubation [19].
3.2. FAD mutations affect the aggregation rate to various extents but
have little effect on ﬁbril morphology and secondary structure
Familial mutations of Ab1–42 displayed a short nucleation phase
similar to that observed for wild type Ab1–42, but affected the rate
Fig. 1. Increased aggregation and oligomerization of Ab with increasing peptide
length. (A) Aggregation of C-terminal varying Ab peptides monitored by ThT
ﬂuorescence. (B) ThT ﬂuorescence intensities after 20 h of incubation. (C) TEM
images of 2 weeks incubated Ab at 25 C. The scale bar represents 0.1 lm. (D) A11-
reactivity of 0.5 h pre-incubated Ab in a dotblot assay. (E) Deconvoluted ATR-FTIR
spectra of Ab peptides (2 lg) recorded after 1.5 h incubation at 25 C.
Table 1
Quantiﬁcation of the secondary structure content using ATR-FTIR. Curve-ﬁtting was
performed on the non-deconvoluted FTIR spectra and resulted in estimated contri-
butions of b-sheets (1613–1637 and 1682–1689 cm1), a-helices and random coil
(1637–1662 cm1), and turns (1662–1682 cm1) to the secondary structure content
of every Ab peptide sample. The b-sheet index is deﬁned as the ratio of the
(1695 cm1/1630 cm1) intensities.
Secondary structure element(%)
Peptide identity b-Sheet Random coil + a-helix Turn b-Sheet index
Ab1–37 36 44 20 0.28
Ab1–38 37 43 20 0.26
Ab1–40 47 33 20 0.27
Ab1–42 55 32 13 0.18
Ab1–43 56 28 16 0.14
D7N Ab1–42 55 30 15 0.19
A21G Ab1–42 51 33 16 0.22
E22G Ab1–42 41 37 22 0.18
E22K Ab1–42 45 39 16 0.16
E22Q Ab1–42 50 32 19 0.21
D23N Ab1–42 46 32 23 0.14
Biotin-Ab1–40 34 44 22 0.31
Ab1–40-K-biotin 42 39 19 0.21
Biotin-Ab1–42 54 34 12 0.17
Ab1–42-K-biotin 44 39 17 0.15
p317–40 39 41 20 0.25
p317–42 49 34 17 0.19
4090 A. Vandersteen et al. / FEBS Letters 586 (2012) 4088–4093of ﬁbril elongation and ﬁnal ThT ﬂuorescence intensity (Fig. 2A,B).
The slow polymerization of the D23N mutation coincided with a
very low ﬁnal ThT ﬂuorescence, while A21G and E22Q mutations
of Ab1–42 aggregated at a higher rate with an increased ﬁnal ThT
ﬂuorescence intensity compared to wild type Ab1–42. All mutants
of Ab1–42 displayed a b-sheet enriched conformation (Fig. 2E,
Table 1) and eventually formed similar dense ﬁbrillar networks
(Fig. 2C). Oligomerization of the mutated Ab1–42 peptides showed
little variability as seen by A11-reactivity (Fig. 2D), with exception
of D23N Ab1–42, and b-sheet index analysis indicated similar oligo-
mer-content for the various peptides (Table 1).
3.3. Biotinylation affects aggregation of Ab1–40 and Ab1–42
N- and C-terminal biotinylation of Ab1–40 increased the lag time
of aggregation (Fig. 3A) while decreasing ﬁnal ThT ﬂuorescence
(Fig. 3A,B), indicative of inhibited aggregation, without affecting ﬁ-
bril morphology (Fig. 3C). Oligomerization of biotinylated Ab1–40,
as probed by A11-reactivity, was unaffected (Fig. 3D). Structural
analysis of the peptides by ATR-FTIR however revealed absorptiondifferences in the 1680–1640 cm1 region (Fig. 3E, Table 1). Biotin-
ylation of Ab1–42 reduced polymerization of the peptide compared
to wild type Ab1–42 (Fig. 3A) without signiﬁcantly affecting ﬁnal
ThT ﬂuorescence (Fig. 3B), ﬁbril morphology (Fig. 3C) or secondary
structure content (Fig. 3E, Table 1). For Ab1–42 the impact of biotin-
ylation on oligomerization depended on the location of the modi-
ﬁcation. C-terminal biotinylation did not affect A11-reactivity
(Fig. 3D) but resulted in a reduced b-sheet index (Table 1). N-ter-
minal modiﬁcation on the other hand strongly impaired A11-reac-
tivity (Fig. 3D) but did not inﬂuence the b-sheet index (Table 1).
The b-sheet index of biotinylated peptides however needs to be
interpreted with caution as the biotin tag might absorb around
1695 cm1 leading to an overestimation of this value.
3.4. N-terminal truncation of Ab induces rapid onset aggregation
Both N-terminally truncated forms of Ab1–40 and Ab1–42, p317–40
and p317–42 respectively, were characterized by rapid onset of
aggregation compared to their corresponding full-length forms
with decreased ﬁnal ThT ﬂuorescence intensity (Fig. 4A,B). From
a morphological perspective, visualization by TEM revealed short
ﬁbrillar fragments for p317–40 dissimilar from the long extended
networks observed for full-length Ab1–40 (Fig. 4C). Truncation of
Ab1–42 to p317–42 only slightly affected ﬁbril morphology resulting
in less curly ﬁbrils (Fig. 4C). Structural analysis by ATR-FTIR indi-
cated that p317–40 displayed less b-sheets and more random coil
and a-helical content than full-length Ab1–40. A similar observation
was made for p317–42 compared to Ab1–42 (Fig. 3E, Table 1). Oligo-
merization of the truncated p3 peptides, as analyzed by A11-reac-
tivity and the b-sheet index, was not signiﬁcantly affected
compared to the full-length counterparts (Fig. 4D, Table 1).
4. Discussion
The in vivo Ab pool contains a high degree of variability, consist-
ing of peptides with C-terminal variations, FAD-related mutations,
and N-terminal truncations. To elucidate the mechanisms leading
to Alzheimer disease (AD) some peptides have been additionally
modiﬁed, e.g. biotinylated, to enable their investigation in experi-
mental research. We chemically synthesized Ab peptide variants
Fig. 2. Some FAD mutations affect aggregation and oligomerization of Ab1–42. (A)
Aggregation of Ab1–42 FAD mutations monitored by ThT ﬂuorescence. (B) ThT
ﬂuorescence intensities after 20 h of incubation. (C) TEM images of 2 weeks
incubated Ab at 25 C. The scale bar represents 0.1 lm. (D) A11-reactivity of 0.5 h
pre-incubated Ab in a dotblot assay. (E) Deconvoluted ATR-FTIR spectra of Ab
peptides (2 lg) recorded after 1.5 h incubation at 25 C.
Fig. 3. C- and N-terminal biotinylation of Ab1–42 and Ab1–40 differentially affect
aggregation. (A) Aggregation of C- and N-terminally biotinylated forms of Ab1-40
and Ab1-42 monitored by ThT ﬂuorescence. (B) ThT ﬂuorescence intensities after
20 h of incubation. (C) TEM images of 2 weeks incubated Ab at 25 C. The scale bar
represents 0.1 lm. (D) A11-reactivity of 0.5 h pre-incubated Ab in a dotblot assay.
(E) Deconvoluted ATR-FTIR spectra of Ab peptides (2 lg) recorded after 1.5 h
incubation at 25 C.
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biophysical techniques. Our observations show that variations in
the Ab sequence can have consequences for the propensity of the
Ab peptide to aggregate and oligomerize.
C-terminal variation was previously shown to affect aggrega-
tion propensity, and it has been generally reported that Ab1–42
aggregates at a higher rate than Ab1-40 [20,21]. Even though
approximately 90% of the Ab peptide pool is composed of these
two peptides, it was recently recognized that also Ab1–37, Ab1–38,
and Ab1–43 are present in the brain and may modulate disease pro-
gress [22]. We show that C-terminal extension generally results in
faster aggregation and gradual transformation into densely net-
worked b-sheet rich aggregates compared to shorter peptides,
which form extended ﬁbrils characterized by a primarily disor-
dered structure. We further observed that Ab1–37 and Ab1–38 gener-
ally behave similar to Ab1–40 while the behavior of Ab1–43 strongly
resembles that of Ab1–42. The dense ﬁbril networks formed by
Ab1–42 and Ab1–43 possibly provide less access to the ThT dye
compared to the more extended ﬁbrils of shorter peptides, resulting
in a lower ﬁnal ThT ﬂuorescence intensity. Alternatively, the den-
ser peptide networks can be more prone to precipitation in the test
tube which would lead to a similar observation. Although the effect
of FAD-related mutations of Ab1–42 on aggregation has beeninvestigated in the past [23–26], no comprehensive study has been
reported that directly compares the majority of the currently
known mutations. Different Ab preparation methods and experi-
mental conditions have led to considerable variation in reported
effects of these mutations. ThT ﬂuorescence data in this study were
measured at a physiologically relevant Ab concentration of 1 lM.
Most FAD-related mutations are located in or near the central
hydrophobic cluster of the Ab peptide, which has been predicted
and reported to play an important role in aggregation [23,27–31].
FAD mutations can thus either inhibit or induce aggregation
depending on the suitability of the replacing amino acid to accom-
modate an amyloidogenic or aggregated structure. Molecular
dynamics simulations have suggested the depletion of the E22-
K28 salt bridge to explain the enhanced aggregation of E22Q
Ab1–42, while the switch of a bend motif to a turn in the region
Ab22–28 could result in slower aggregation of the D23N Ab1–42 mu-
tant [25]. Overall ﬁbril morphology is however not affected, as has
Fig. 4. p3 Peptides show pronounced aggregation. (A) Aggregation of p317–40 and
p317–42 monitored by ThT ﬂuorescence. (B) ThT ﬂuorescence intensities after 20 h of
incubation. (C) TEM images of 2 weeks incubated Ab at 25 C. The scale bar
represents 0.1 lm. (D) A11-reactivity of 0.5 h pre-incubated Ab in a dotblot assay.
(E) Deconvoluted ATR-FTIR spectra of Ab peptides (2 lg) recorded after 1.5 h
incubation at 25 C.
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tral hydrophobic region is however not the absolute key in deter-
mining aggregation tendency as a subset of the FAD mutations in
this region has no effect on the aggregation rate and most likely ex-
ert their pathological function through aberrant APP processing or
reduced proteolytic Ab degradation [32–34]. We further show that
C-terminal elongation, which does not affect the central region of
Ab, also affects aggregation. Moreover, complete destruction of
the central aggregation zone by deletion of the ﬁrst 17 N-terminal
amino acids, as naturally occurs by APP processing via the non-
amyloidogenic pathway, does not abolish the aggregating charac-
ter of the peptides, as was observed before [35] and upregulation
of the a-secretase cleavage pathway initiating the non-amyloido-
genic processing of APP has served as a template for the generation
of various potential disease modulating drugs [36]. It is thus likely
to suggest that, even though the central Ab region can play a reg-
ulating role in the aggregation process, the C-terminal region
may dominate this effect by determining ﬁbril morphology. Biotin-
ylation of Ab has been applied in several studies [9–12]. Our data
show that this modiﬁcation can affect the onset of aggregationsubstantially depending on the type of biotinylation applied and
its location, either N- or C-terminally, without affecting ﬁbril mor-
phology or oligomer formation. These observations underline the
importance of selecting and validating the type of labeling required
for experiments without inducing changes in the peptide behavior
that are subject to study.
In this work we systematically compared a wide range of Ab
peptides for their aggregation properties. The overall aggregation
proﬁle was determined by thioﬂavin T ﬂuorescence while we at-
tempted to gain insight in early aggregation events by probing
oligomerization of the peptides. We therefore used A11-reactivity
as well as analysis of secondary structure content which were
however not always completely in agreement. This could be attrib-
uted to the polyclonal nature of the A11 antibody [14] that can be
hypothesized to recognize more than one conformation. On the
other hand, it might be likely that both methods detect different
oligomeric species. In conclusion, the results highlight that minor
sequential variations may have consequences for the aggregation
of Ab.
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